American Society on Aging (ASA) – Andrew Dougherty Medinteract President to present on Diagnosising Different Types of Dementia at ASA Conference in Chicago, March 24, 2015

Diagnosing dementia in the family practice setting has always been a challenge. Join us March 24th from 9:00 to 10:30 AM and learn how medical imaging and cognitive testing is being used today to diagnose the different types of dementia.

At the 2015 Aging in America Conference, Sue and her colleagues will present “Diagnosing Different Types of Dementia: Cognitive Testing and Medical Imaging” on Tuesday, March 24, 9-10:30 AM in Soldier Field at the Hyatt Regency Chicago. You can search the entire program via our website and get the conference app.

We are so excited to be presenting at this years Aging in America Conference! This is our second year to present and we have created an engaging workshop titled, “Diagnosing the Different Types of Dementia: The Evolution of Cognitive Testing and Medical Imaging.” We will provide a comprehensive program because there are some serious questions to be answered when it comes to knowing what testing is available and how it is being used. Nearly fifty percent of individuals are not given an appropriate dementia diagnosis until it is too late for available treatment options, or to participate in clinical trials.

Ruth Tesar will begin our workshop with a detailed update on the status of routine and advanced medical imaging for dementia, including PET and MRI. What are the newest imaging agents and what is in the pipeline? Ruth will discuss which imaging tests are appropriate and available, as well as help you understand what role they play in getting to a diagnosis, answering the question, “what is the right test at the right time?”

Sue Halliday will discuss the development of diagnostic algorithms and help you understand how they are used in routine clinical practice. Sue will provide updates on private payer and Medicare guidelines for routine cognitive testing as well as coverage guidelines for diagnostic imaging. What tests are covered and paid for by the different payers and Medicare? She will also provide an update on the status of medical imaging within the large clinical trials.

Andrew Dougherty will discuss the role of cognitive testing in the primary care and neurology practice setting. What are the different tests, what do the results tell your physician and when is it appropriate to obtain more comprehensive tests? Andrew will give an overview of all the primary forms of dementia. The talk will cover screening for areas of cognitive function including: executive function, verbal fluency, visual-spatial, memory, attention and orientation and why it is imperative to test each domain. Andrew will also focus on specific preventative treatment options for each cognitive domain and how it can improve overall cognitive function. Also included will be a brief review of recent studies on diet/nutrition and physical exercise as preventative measures to delay the onset of dementia.

  • News
  • March 13th, 2015

COGselftest creator discussing the new Pat Summitt Alzheimer’s Clinic at the University of Tennessee Medical Center

Here is an update on the Pat Summitt Alzheimer’s Clinic. The University of Tennessee Medical Center and the Pat Summitt Foundation are partnering to establish the Pat Summitt Alzheimer’s Clinic.

Dr. Dougherty and Joan Cronan share their vision of this new project.

Congratulations Knoxville! We will keep you posted with all the updates!

Medinteract and Summit Medical Group Announce Rollout of Early Cognitive Impairment Screening Test

Medinteract’s COGselftest™ to be deployed through Summit Medical Group to improve early identification of cognitive impairment, including Alzheimer’s disease


Knoxville, TN – November 5, 2012 – Medical Interactive Education, LLC (Medinteract), a cognitive wellness company, and Summit Medical Group, a leading primary care provider, announced today that the Medinteract COGselftest (CST™) will begin to rollout in Summit locations throughout East Tennessee.   The CST, a computer-based, clinically-validated cognitive wellness screening tool for consumers, will roll out this fall to Summit’s 220 physicians and more than 70 nurse practitioners in 58 sites serving approximately  300,000 patients in East Tennessee.  The CST has been shown to detect cognitive impairment in its earliest stages and is uniquely capable of differentiating the various forms of disease, including Alzheimer’s and frontotemporal dementia.  The test is available on portable computing devices, including the Apple iPad, can be self-administered, and takes about eight minutes to complete.


“Summitshares our commitment to improving the identification and treatment of cognitive loss,” said Medinteract founder and president Andrew Dougherty. “We believe that early screening in the primary care setting is the key to improved management and treatment of cognitive impairment such as Alzheimer’s disease.  We are providing our partners with the first clinically-proven, electronic test capable of differentiating the various forms of dementia so that effective treatment plans can be administered to delay onset of symptoms.  We are excited to announce our collaboration withSummitand look forward to continuing to deploy the CST with our primary care physician group partners.”


“Providing innovative, quality disease screening and diagnostic services to our patients is a priority forSummit,” commented Jack Kam, Vice President of Ancillary Services and Business Development at Summit Medical Group.  “As the first major primary care provider organization to offer the CST,Summitcontinues to deliver on that priority.  We tested the CST through a 6-month pilot program and were impressed with the quality and depth of information that the test results provide our physicians, as well as the ease-of-use of the test. We look forward to working with Medinteract to make a difference in the fight against Alzheimer’s and related dementias.”


The CST is the first test to screen all six cognitive domains, which is critical to accurately detect the various forms and degrees of impaired cognition and tailor an appropriate management plan for the patient.  The test is reimbursable by Medicare in a physician’s office, takes less than 10 minutes, and provides an immediate and objective cognitive score that can be tracked over time.  In peer-reviewed research and ongoing clinical trials, the CST demonstrates over 98% accuracy rates in identifying cognitive impairment.


Dr. John Dougherty, Chief Medical Officer of Medinteract, stated, “The goal of the CST is to accurately identify those patients with early cognitive impairment.  Through early and accurate identification, one can delay symptom progression  – if one can simply delay symptoms by five years with appropriate medication and exercise, one can reduce the number of individuals with Alzheimer’s disease in the U.S. by six- to-eight million.”


About Medinteract

Medinteract was founded in 2004 by Dr. John Dougherty,  a neurologist specializing in Alzheimer’s Disease, with the purpose of improving the identification and treatment of cognitive impairment.  The company’s CST is the first rapid, clinically-validated electronic test that differentiates the various forms of dementia.  The test is available through Medinteract’s rapidly growing physician network and will soon be available directly to consumers online.  Please visit for more information.


About Summit Medical Group

Summit Medical Group was formed in 1995 by 37 primary care physicians, and has since grown to comprise 220 physicians at 58 practice locations in 11 East Tennesseecounties.  Summitemploys over 1,100 employees, has four ancillary imaging centers, three after-hours Summit Express Clinics, four physical therapy centers, and a central laboratory that runs 4.7 million tests annually. Summitprovides healthcare services to an average of 81,000 patients each month and is dedicated to offering value-based care coordination and improved clinical outcomes through the region’s largest Accountable Care Organization, Summit Health Solutions. For more information about Summit Medical Group, visit


Contact Information:

Medical Interactive Education                                 Summit Medical Group

Andrew Dougherty                                                        Jennifer Burke

President                                                                            Corporate Communications Manager

(877) 259-7353, Ext 1                                                  (865) 584-4747, Ext. 245                        


Alzheimer’s Research in Tennessee – Dr. John Dougherty

Medinteract’s co-founder, Dr. John Dougherty and Dr. Alan Solomon from the University of Tennessee Medical Center, discuss the exciting research collaboration with Eli Lilly and Co. and the newly FDA-approved Amyvid which is used in the early diagnosis of mild cognitive impairment (MCI) and early Alzheimer’s disease.

Dr. Monica Crane Discusses Pat Summitt’s Impact on AD

Dr. Monica Crane, one of our advising physicians, recently spoke with WATE News about Pat Summitt’s impact on the Alzheimer’s community.

Pat Summitt to receive Presidential Medal of Freedom

Congratulations to Pat Summitt for being awarded the Presidential Medal of Freedom!  She has been a role model to millions of people throughout her career and has recently become a key figure in the fight against Alzheimer’s.  Her courage in publicly announcing her diagnosis has brought needed awareness to the disease and stressed the importance of early detection.  As a member of the Knoxville community, we are excited to support Pat Summitt and her foundation in the fight against Alzheimer’s disease.

Dr. Monica Crane – Discusses Alzheimer’s Disease

Dr. Monica Crane, at the University of Tennessee Medical Center and Cole Neuroscience Center discusses Alzheimer’s Disease symptoms and treatment options in a short video produce by UT Medical Center.



Sports Illustrated – Finding a Cure

Medinteract Co-founder, Dr. John Dougherty, was quoted in the article “Finding A Cure” by Alexander Wolf in the December 12, 2011 issue.

Excerpt  – “Early diagnosis is so important,” says Dr. John Dougherty, who runs the Memory Clinic at the University of Tennessee’s Cole Neuroscience Center. “The goal is prevention through delay. If we can delay symptoms by five years with medication and exercise, we can reduce the number of sufferers by six- to eight million—[about] the population of metropolitan Atlanta.”

View the full article

The cover featured: Sportsman Of The Year: Mike Krzyzewski / Sportswoman Of The Year: Pat Summitt

The two winningest coaches in Division I college basketball history (907 for him, 1,075 for her) have more in common than just extraordinary success. For reaching far beyond their campuses and refusing to be defined by their genders, SI honors them together.

Medinteract – Selected as the 2011 Technology Company of the Year

Tech 2020′s Tennessee Valley Technology Council presented its annual Navigator Awards Wednesday, November 16, during the first day of the Entrepreneurial Imperative 2011 Conference. Awards of excellence were given for this year’s top entrepreneur, researcher, and technology company, as well as for the Tech Commericalization Champion of the year.

Selected as the 2011 Technology Company of the Year, Medinteract  was cofounded by Andrew Dougherty. Medinteract provides efficient and effective detection of Alzheimer’s disease by their computer based cognitive screening testing technology. Early detection leads to early intervention delaying the impact of the disease. Medinteract is now providing their detection services to a range of medical service providers across the region.

See the full release from Tech2020’s Tennessee Valley Technology Council.

Dr. Dougherty Part of Grant Presentation from Pat Summit Foundation to UT Medical Center and Alzheimer’s Tennessee, Inc

Co-Founder of Medinteract, Dr. John Dougherty, was part of a check presentation to the UT Medical Center from the Pat Summit Foundation on behalf of the “We Back Pat” promotion at half time of the University of Tennessee versus Baylor game on Sunday,  November 27, 2011.  The event raised $150,000 and was generated grants to the UT Medical Center’s Brain and Spine Institute and Alzheimer’s Tennessee, Inc.

Click here to see the Presentation

About Pat Summit Foundation

The Pat Summit Foundation Fund believes no family should have to hear a diagnosis like Pat’s: early onset dementia, Alzheimer’s type.  The Fund will make grants to nonprofits which provide:

  1. Education and awareness of Alzheimer’s its onset and treatment,
  2. Support services to patients, their families and caregivers,
  3. Research to treat, prevent, cure and ultimately eradicate this disease.

About Alzheimer’s Tennessee, Inc

In 1983, a small group of East Tennessee families began to meet informally in an effort to understand and cope with the ravaging effects of Alzheimer’s disease. Together, the group was able to anticipate, confront, and solve seemingly insurmountable problems with a renewed sense of hope, confidence and accomplishment.

Alzheimer’s Tennessee, Inc. began providing services in East Tennessee as a non-profit organization in 1983. Two years later, the group affiliated with the Chicago-based National Alzheimer’s Association and became known as the Alzheimer’s Association, Eastern Tennessee Chapter, Inc. However, it always remained incorporated in the state of Tennessee and governed by a local Board of Directors.

The Eastern Tennessee Chapter of the Alzheimer’s Association returned to its original independent status in August 2011 to ensure that more resources support top research and local services for individuals and families struggling with the devastating disease.

About UT Medical Center and the Cole Neuroscience Center

The Cole Neuroscience Center is the only Neurology sub-specialty center of its kind in the region, The Cole Neuroscience Center offers a complete spectrum of care for degenerative neurological diseases, such as Alzheimer’s, Dementia, Movement Disorders, Parkinson’s, Multiple Sclerosis, Muscular Dystrophy, Amyotrophic Lateral Sclerosis and Epilepsy. Our specialists work together to develop treatment plans that assist the entire family. From access to the latest diagnostic tools and the newest clinical trials, to offering counseling and long-term care options, the Cole Neuroscience Center has so much to offer – especially hope. Each year the Cole Neuroscience Center serves more than 1400 patients with Parkinson’s disease, 2000 with Alzheimer’s disease and numerous others with neurodegenerative diseases.